Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 08, 2023

SELL
$65.71 - $74.53 $2,365 - $2,683
-36 Reduced 1.2%
2,953 $204,000
Q4 2022

Feb 06, 2023

BUY
$68.48 - $81.09 $5,272 - $6,243
77 Added 2.64%
2,989 $215,000
Q3 2022

Nov 07, 2022

SELL
$0.13 - $76.84 $10 - $5,916
-77 Reduced 2.58%
2,912 $207,000
Q1 2022

May 10, 2022

BUY
$61.48 - $73.72 $183,763 - $220,349
2,989 New
2,989 $218,000
Q4 2021

Jan 28, 2022

SELL
$53.63 - $62.52 $174,565 - $203,502
-3,255 Closed
0 $0
Q2 2021

Aug 03, 2021

SELL
$61.91 - $67.42 $80,359 - $87,511
-1,298 Reduced 28.51%
3,255 $217,000
Q1 2021

Apr 27, 2021

SELL
$59.34 - $66.74 $36,553 - $41,111
-616 Reduced 11.92%
4,553 $287,000
Q4 2020

Jan 27, 2021

SELL
$57.74 - $65.43 $4,215 - $4,776
-73 Reduced 1.39%
5,169 $321,000
Q2 2020

Aug 04, 2020

SELL
$54.82 - $64.09 $9,538 - $11,151
-174 Reduced 3.21%
5,242 $308,000
Q1 2020

Apr 21, 2020

SELL
$46.4 - $67.43 $4 Million - $5.81 Million
-86,209 Reduced 94.09%
5,416 $302,000
Q4 2019

Feb 07, 2020

SELL
$49.21 - $64.19 $3.39 Million - $4.42 Million
-68,851 Reduced 42.9%
91,625 $5.88 Million
Q3 2019

Oct 28, 2019

BUY
$42.77 - $50.71 $86,609 - $102,687
2,025 Added 1.28%
160,476 $8.14 Million
Q2 2019

Jul 10, 2019

BUY
$44.62 - $49.34 $7.07 Million - $7.82 Million
158,451 New
158,451 $7.22 Million
Q4 2018

Jan 15, 2019

SELL
$48.76 - $63.23 $3,657 - $4,742
-75 Closed
0 $0
Q3 2018

Nov 05, 2018

SELL
$55.19 - $62.25 $8,278 - $9,337
-150 Reduced 66.67%
75 $5,000
Q2 2018

Aug 06, 2018

SELL
$50.53 - $62.98 $5,053 - $6,298
-100 Reduced 30.77%
225 $4,000
Q3 2017

Feb 05, 2019

BUY
$55.23 - $63.74 $8,284 - $9,561
150 Added 85.71%
325 $21,000
Q2 2017

Feb 04, 2019

BUY
N/A
175
175 $10,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Rpg Investment Advisory, LLC Portfolio

Follow Rpg Investment Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rpg Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rpg Investment Advisory, LLC with notifications on news.